Recruiting

Testing a new injection for kidney inflammation from lupus

Plain-English translation of NCT07229742 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a Phase II trial testing , a new medication designed to help treat lupus nephritis—a serious condition where lupus damages the kidneys. About half of participants will receive the medication while the other half receive a placebo (dummy injection), and neither you nor the study team will know which one you're getting. Researchers want to see if this treatment can safely reduce kidney inflammation and improve kidney function in people with active lupus nephritis.

Lupus nephritis is a severe complication of lupus that can lead to kidney failure if not well controlled, and current treatments don't work well enough for everyone. This trial is exploring whether this medication could offer a new, safer option to help protect kidneys and prevent lasting damage.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with lupus according to standard medical criteria
you have had a kidney biopsy confirming active lupus nephritis (class III or IV, with or without class V)
you have specific lupus antibodies in your blood (antinuclear antibody, anti-dsDNA, or anti-Sm)
your body weight is at least 40 kg and your BMI is between 16 and 28 kg/m²

You likely don't qualify if…

you have received kidney dialysis in the past 12 months or will need it soon
your kidney biopsy shows more than 50% scarring (globally sclerosed glomeruli)
you have active severe or unstable neuropsychiatric lupus symptoms
you have had catastrophic antiphospholipid syndrome or blood clots related to antiphospholipid syndrome in the past year
you have other kidney diseases (like diabetic kidney disease) that could affect how the study results are interpreted

What participation looks like

You will be randomly assigned to receive either the new medication or a placebo injection at multiple study visits over several months. The study team will monitor your kidney function, lupus activity, and any side effects through blood tests and clinical exams. This is a double-blind study, meaning neither you nor your doctors will know which treatment you're receiving until the trial ends, ensuring fair and unbiased results.

AI-generated summary from trial data · Jun 11, 2026 · Not medical advice

Trial locations(1 site)

China

The General Hospital of the Eastern Theater Command of the People's Liberation Army of China, Nanjing, Jiangsu